Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Study to Measure the Safety of 68Ga-DOTA-TATE PET/CT in the Diagnosis of Tumors Expressing Somatostatin Receptors

NCT02810600 is registered in ClinicalTrials.gov with Centre de recherche du Centre hospitalier universitaire de Sherbrooke as lead sponsor.

NCT NCT02810600
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02810600 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Study to Measure the Safety of 68Ga-DOTA-TATE PET/CT in the Diagnosis of Tumors Expressing Somatostatin Receptors
Lead sponsor
Centre de recherche du Centre hospitalier universitaire de Sherbrooke
Phase
Observational
Overall status
Completed
Start date
June 8, 2016
Completion date
May 29, 2020
Enrollment
2,120 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

neuroendocrine tumors